Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.55 |
| ▸ | MAP3K11 | Q16584 | 8/20 | 0.49 |
| ▸ | TNIK | Q9UKE5 | 9/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.47 |
| ▸ | PRKCG | P05129 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.47 |
| ▸ | MARK3 | P27448 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129778 | 0.92 | GSK3B (0.48) | MAP4K1TNIKCDK2FLT3CHEK1 | |
| SCHEMBL18129509 | 0.92 | MAP3K11 (0.52) | MAP4K1MAP3K11TNIKCDK2FLT3 | |
| SCHEMBL18129615 | 0.90 | MAP4K1 (0.45) | MAP4K1MAP3K11TNIKCDK2FLT3 | |
| SCHEMBL18129531 | 0.90 | MAP4K1 (0.45) | MAP4K1MAP3K11TNIKCDK2FLT3 | |
| SCHEMBL18129463 | 0.89 | MAP4K1 (0.58) | MAP4K1MAP3K11TNIKCDK2FLT3 | |
| SCHEMBL18129605 | 0.89 | MAP3K11 (0.49) | MAP4K1MAP3K11TNIKCDK2FLT3 | |
| SCHEMBL18129472 | 0.88 | CHEK1 (0.46) | MAP4K1CDK2FLT3CHEK1MAP4K4 | |
| SCHEMBL18129776 | 0.87 | GSK3B (0.47) | MAP4K1CDK2FLT3CHEK1MAP4K4 | |
| SCHEMBL18129593 | 0.86 | MAP4K1 (0.55) | MAP4K1MAP3K11TNIKCDK2FLT3 | |
| SCHEMBL18129490 | 0.86 | CHEK1 (0.53) | MAP4K1MAP3K11CDK2FLT3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | claimed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | claimed |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TANK, NFKBIA, TBK1 | MAP4K1 766/4885MAP3K11 519/4885TNIK 14/4885 |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | NFKBIA, TANK, TBK1 | MAP4K1 858/4885MAP3K11 600/4885TNIK 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.